Fulgent Genetics, Inc. (FLGT) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Fulgent Genetics operates two primary segments: Laboratory Services (diagnostic testing and pathology) and Therapeutic Development (cancer drug candidates). A significant event during the quarter was the acquisition of Bako Diagnostics and StrataDx (collectively the "Bako Acquisition") on March 17, 2026, for approximately $55.7 million net of cash. The acquisition is integrated into the Laboratory Services segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $71.1 million | $73.5 million |
| Gross Profit | $21.5 million | $28.3 million |
| Gross Margin | 30.2% | 38.6% |
| Operating Loss | $(34.6) million | $(19.8) million |
| Net Loss (Attributable to Fulgent) | $(24.8) million | $(11.5) million |
| Diluted EPS | $(0.80) | $(0.37) |
| Cash from Operations | $7.1 million | $(4.4) million |
| Cash & Marketable Securities | $604.7 million | $705.5 million (Dec 31, 2025) |
| Debt (Notes Payable) | $2.0 million | $2.0 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 3% year-over-year. This was driven by a 9% decline in Precision Diagnostics ($40.2M vs $44.1M) and a 1% decline in Anatomic Pathology. The drop in Precision Diagnostics is attributed to the largest customer (15% of Q1 2026 revenue) transitioning testing services in-house.
- Margin Compression: Gross margin contracted from 39% to 30%. Cost of revenue increased 10% due to higher personnel expenses, shipping, and reagent costs, partially driven by the integration of the Bako Acquisition (included for ~2 weeks).
- Expense Growth: Operating expenses rose 17% to $56.1 million. Selling and marketing expenses surged 44% due to increased headcount and software licensing. General and administrative expenses increased 9%, largely due to $2.6 million in acquisition-related costs for the Bako deal.
- Stock Repurchases: The company repurchased 2.6 million shares for $40.1 million during the quarter. As of March 31, 2026, $99.6 million remained available under the $250 million program.
Outlook, Risks, and Contingencies
- Customer Concentration Risk: The company expects revenue from its largest customer to continue declining in 2026 as they internalize testing. Management is focusing on diversifying the customer base.
- Legal Proceedings: The company is subject to ongoing investigations, including a Civil Investigative Demand (CID) from the DOJ regarding the False Claims Act and an audit by HRSA regarding COVID-19 test reimbursements. A qui tam complaint was recently dismissed without prejudice. The company has accrued $14.5 million for a professional liability settlement but cannot estimate losses for ongoing government investigations.
- Acquisition Integration: The Bako Acquisition is expected to impact consolidated results more significantly in Q2 2026 and beyond. Management anticipates higher operating expenses as integration continues.
- Therapeutic Development: R&D expenses for the therapeutic segment increased 7%, driven by clinical studies for FID-007 and FID-022. Timelines remain subject to FDA review capabilities.
Investor Verification Checklist
- Customer Concentration: Verify the specific timeline and magnitude of revenue loss from the largest customer transitioning to in-house testing.
- Acquisition Synergies: Assess the integration progress of Bako Diagnostics and StrataDx and the realization of projected cost savings or revenue synergies.
- Legal Exposure: Monitor updates on the DOJ CID and HRSA audit outcomes, as potential fines or repayments could materially impact liquidity.
- Cash Burn vs. Liquidity: Confirm that the $604.7 million in liquid assets remains sufficient to fund operations, clinical trials, and the stock repurchase program given the widening operating loss.
- Reimbursement Rates: Evaluate the impact of insurance payor reimbursement rates on the gross margin trajectory, particularly for the precision diagnostics segment.